DeGlyPHER-ing Site-Specific Distribution of N-Glycans on Candidate Vaccines Against HIV Using PAMAF

Discover how the Yates lab uses MOBILion’s PAMAF technology as part of their DeGlyPHER workflow to revolutionize vaccine development by analyzing site-specific N-glycosylation for improved antigenicity, immunogenicity, and consistency.

Register Free: https://www.chromatographyonline.com/lcgc_w/pamaf

Event Overview:

Join for an insightful presentation on how John Yates’ lab is leveraging MOBILion’s new Parallel Accumulation Mobility Aligned Fragmentation (PAMAF) technology as part of their DeGlyPHER (Deglycosylation-dependent Glycan/Proteomic Heterogeneity Evaluation Report) workflow for deeper characterization of the SARS-CoV-2 viral spike protein. DeGlyPHER is a rapid and reproducible approach designed to assess site-specific N-glycosylation in candidate vaccines. Combining this elegant approach with the PAMAF operating mode that improves the speed and sensitivity of LC-MS fragmentation analysis results in new insights about glycosylation modifications, which can impact the antigenicity and immunogenicity of therapeutic vaccines.

DeGlyPHER has already been used to evaluate over 200 immunogens for vaccines targeting major pathogens like HIV, SARS-CoV-2, Influenza, and Ebola, providing groundbreaking insights into glycan distribution and processing. By generating overlapping peptides and utilizing sequential deglycosylation with Endo H and PNGase F, this method enables precise quantification of glycan occupancy and characterizes glycan processing, offering a deeper understanding of how glycosylation shapes immune response.

Don’t miss this opportunity to learn how DeGlyPHER is transforming vaccine development in real-time and driving progress toward more effective and consistent immunization strategies while also delivering a more sensitive and high-throughput approach compared to traditional glycoproteomic methods.

Key Learning Objectives:

• Understand the Importance of N-Glycosylation in Vaccine Development: Learn how site-specific N-glycosylation impacts antigenicity, immunogenicity, and the consistency of GMP-grade vaccine production.
• xplore the DeGlyPHER Methodology: Gain insights into the DeGlyPHER approach, including its use of sequential deglycosylation and mass spectrometry to quantify glycan occupancy and characterize glycan processing in vaccine candidates.
• Learn about PAMAF: This is a novel LC-MS operating mode that leverages high resolution ion mobility for precursor ion selection instead of the traditional quadrupole to improve the speed and sensitivity of analysis
• Apply DeGlyPHER Findings to Vaccine Design: Learn how DeGlyPHER has contributed to the development of HIV, SARS-CoV-2, and other vaccines by informing key glycan-related design decisions that enhance immune response and vaccine efficacy.
  
  Who Should Attend:
• Glycobiologists
• Academia
• Biotechnology
• Drug development
• R&D
• Vaccine development scientists
• Mass spectrometry specialists
• Proteomics researchers
• Biopharmaceutical R&D scientists
• Analytical chemists (specializing in biopharma)

Speaker:

John R. Yates III, PhD
Professor
The Scripps Research Institute

John R. Yates III, PhD, is the Ernest W. Hahn Professor in the departments of molecular medicine and neurobiology at The Scripps Research Institute. His research interests include development of integrated methods for tandem mass spectrometry analysis of protein mixtures, bioinformatics using mass spectrometry data, and biological studies involving proteomics. He has received numerous awards and published over 1000 scientific articles with >173,000 citations.

Register Free: https://www.chromatographyonline.com/lcgc_w/pamaf